Page 29 - Seth Lederman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Company updates plans for commercial vaccine manufacturing facility in Hamilton Dennis Bragg photo and last updated 2021-06-25 01:55:36-04 HAMILTON — A New Jersey-based pharmaceuticals company says its on track to build a new, commercial scale vaccine manufacturing facility in the Bitterroot Valley. Tonix Pharmaceuticals first announced plans to locate one of its operations on the east side of Hamilton last winter. And this week, company officials are in town for further discussions with Ravalli County and Hamilton leaders. Plans are to build on 44-acres of land off Old Corvallis Highwa...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced the poster presentation of previously reported results from its ...

Share: Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia  Expected in Third Quarter 2021 Deep Pipeline Progressing with Three Central Nervous System  (CNS) Programs Expected to Enter Phase 2 Trials This Year At March 31, 2021, Cash and Cash Equivalents Totaled Approximately $164 Million CHATHAM, N.J., May 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 and provided an overview of recent operatio...

GB Sciences Featured & Speaking at the SACHS Associates' 4th Annual Neuroscience Innovation Forum LAS VEGAS, NV / ACCESSWIRE / April 27, 2021 / GB Sciences (GBS), Inc. (OTCQB:GBLX), a leading phytomedicine research and biopharmaceutical development company, will be featured during the SPOTLIGHT SHOWCASE at the SACHS Associates' 4th Annual Neuroscience Innovation Forum (NIF) for Business Development, Licensing & Investment from April 28 to April 30. The SACHS NIF, which is entirely virtual, will include a SPOTLIGHT SHOWCASE session describing GB Sciences' recent pivot and novel drug developme...

Tonix Pharmaceuticals forms exclusive licensing agreement develop a potential coronavirus treatment Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has formed an exclusive licensing agreement develop a potential coronavirus treatment, TNX-3500, from OyaGen, Inc. a pre-clinical biotechnology research company. Dr Lederman says in TNX-3500 is '65 times more potent' than Gilead's Remdesivir, in-vitro, at inhibiting the coronavirus. He adds the group is very excited to move TNX-3500 into animal studies, and later clini...